‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’
Background Within the context of increasing transparency around public contributions, a framework for reporting and analysing public contributions to research and development (R&D) was previously developed and is piloted here using the example of antibiotics. The aim of this work is to check whe...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20523211.2024.2449045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592294096666624 |
|---|---|
| author | Louise Schmidt Ozren Sehic Ursula Theuretzbacher Daniel Fabian Claudia Wild |
| author_facet | Louise Schmidt Ozren Sehic Ursula Theuretzbacher Daniel Fabian Claudia Wild |
| author_sort | Louise Schmidt |
| collection | DOAJ |
| description | Background Within the context of increasing transparency around public contributions, a framework for reporting and analysing public contributions to research and development (R&D) was previously developed and is piloted here using the example of antibiotics. The aim of this work is to check whether the category system is feasible, to revise and adjust the granularity of the category system where necessary, and to expand the range of sources for detailed analyses.Methods All antimicrobial medicinal products in development, discontinued and approved in the last 10 years were identified in the literature. Thereafter clinical trials and company information was searched generating a list of 56 compounds where primarily small to medium-sized enterprises (SMEs) were involved in antibiotics development. Information on clinical trials, university spinouts and public funding for SMEs was then gathered from various sources. The framework for classifying public contributions was then applied.Results We found that around one-third of antibiotics are developed by SMEs. We identified numerous public funding sources for SMEs that develop antibiotics. At both early-stage and late-stage development, public research funding is the most common public funding reported by SMEs, ahead of other public sources like public equity funds, private-public partnerships and philanthropic sources. A deep-dive into one antibiotic drug, Venatorx, revealed public funds investment of approximately $655 million, dwarfing private investment funds. We found the classification framework generally practicable and we suggest recommendations to improve its granularity and applicability.Conclusion In this paper we piloted and revised a framework that has been developed to classify types of public contributions to pharmaceutical products at different stages of development. The framework, together with work we have done on identifying sources for funding, can be applied to support pharmaceutical price negotiations that reflect the level of public contribution to product development.Trial registration: EU Clinical Trials Register identifier: 0004-2083-2207.Trial registration: EU Clinical Trials Register identifier: 0003-1754-9422. |
| format | Article |
| id | doaj-art-83e23bbf64e8432c89ef31ddf2a2cbc2 |
| institution | Kabale University |
| issn | 2052-3211 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj-art-83e23bbf64e8432c89ef31ddf2a2cbc22025-01-21T11:39:04ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112025-12-0118110.1080/20523211.2024.2449045‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’Louise Schmidt0Ozren Sehic1Ursula Theuretzbacher2Daniel Fabian3Claudia Wild4Austrian Institute for Health Technology Assessment (AIHTA), Vienna, AustriaAustrian Institute for Health Technology Assessment (AIHTA), Vienna, AustriaCenter for Anti-Infective Agents, Vienna, AustriaAustrian Institute for Health Technology Assessment (AIHTA), Vienna, AustriaAustrian Institute for Health Technology Assessment (AIHTA), Vienna, AustriaBackground Within the context of increasing transparency around public contributions, a framework for reporting and analysing public contributions to research and development (R&D) was previously developed and is piloted here using the example of antibiotics. The aim of this work is to check whether the category system is feasible, to revise and adjust the granularity of the category system where necessary, and to expand the range of sources for detailed analyses.Methods All antimicrobial medicinal products in development, discontinued and approved in the last 10 years were identified in the literature. Thereafter clinical trials and company information was searched generating a list of 56 compounds where primarily small to medium-sized enterprises (SMEs) were involved in antibiotics development. Information on clinical trials, university spinouts and public funding for SMEs was then gathered from various sources. The framework for classifying public contributions was then applied.Results We found that around one-third of antibiotics are developed by SMEs. We identified numerous public funding sources for SMEs that develop antibiotics. At both early-stage and late-stage development, public research funding is the most common public funding reported by SMEs, ahead of other public sources like public equity funds, private-public partnerships and philanthropic sources. A deep-dive into one antibiotic drug, Venatorx, revealed public funds investment of approximately $655 million, dwarfing private investment funds. We found the classification framework generally practicable and we suggest recommendations to improve its granularity and applicability.Conclusion In this paper we piloted and revised a framework that has been developed to classify types of public contributions to pharmaceutical products at different stages of development. The framework, together with work we have done on identifying sources for funding, can be applied to support pharmaceutical price negotiations that reflect the level of public contribution to product development.Trial registration: EU Clinical Trials Register identifier: 0004-2083-2207.Trial registration: EU Clinical Trials Register identifier: 0003-1754-9422.https://www.tandfonline.com/doi/10.1080/20523211.2024.2449045Antibioticsantibacterial agentspublic return on public investments (PRoPI)transparencyresearch and development (R&D)pharmaceuticals |
| spellingShingle | Louise Schmidt Ozren Sehic Ursula Theuretzbacher Daniel Fabian Claudia Wild ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ Journal of Pharmaceutical Policy and Practice Antibiotics antibacterial agents public return on public investments (PRoPI) transparency research and development (R&D) pharmaceuticals |
| title | ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ |
| title_full | ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ |
| title_fullStr | ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ |
| title_full_unstemmed | ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ |
| title_short | ‘Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus’ |
| title_sort | piloting a framework for analysing the public contributions to r d new antibiotics in focus |
| topic | Antibiotics antibacterial agents public return on public investments (PRoPI) transparency research and development (R&D) pharmaceuticals |
| url | https://www.tandfonline.com/doi/10.1080/20523211.2024.2449045 |
| work_keys_str_mv | AT louiseschmidt pilotingaframeworkforanalysingthepubliccontributionstordnewantibioticsinfocus AT ozrensehic pilotingaframeworkforanalysingthepubliccontributionstordnewantibioticsinfocus AT ursulatheuretzbacher pilotingaframeworkforanalysingthepubliccontributionstordnewantibioticsinfocus AT danielfabian pilotingaframeworkforanalysingthepubliccontributionstordnewantibioticsinfocus AT claudiawild pilotingaframeworkforanalysingthepubliccontributionstordnewantibioticsinfocus |